Abstract:Mantle cell lymphoma (MCL) is a rare type of B-cell-derived non-Hodgkin's lymphoma. In Europe and the United States, the overall incidence of MCL is about 0.5 per 100,000 people, accounting for 2% to 10% of all non-Hodgkin lymphomas. [ 1 ] In recent years, the incidence of MCL has shown an increasing trend, [ 1 ] which may be related to the improvement of diagnostic levels. The male-to-female ratio is 2.3 to 2.5:1, and the median age of diagnosis is about 70 years in Europe and the United States. [ 1 ] The median age of onset of MCL in China was 58 years, accounting for 3.07% of the total lymphoma, [ 2 ] with a male-to-female ratio of about 2:1. [ 2 ] MCL combines the clinical presentation of aggressive lymphoma with the therapeutic response of inert lymphoma and is still a disease with an unmet therapeutic need. Current National Comprehensive Cancer Network guidelines, European Society for Medical Oncology (ESMO) guidelines, and Chinese Society Of Clinical Oncology (CSCO) guidelines, although there is no standard treatment for first-line MCL, have reduced the status of R-cyclophosphamide + aclarubicin + vincristine + prednisone (CHOP) or CHOP-like protocols. In fit patients with age, younger than 65 years old, rituximab in combination with high-dose Ara-C followed by is recommended, followed by 12 courses of rituximab maintenance once every 2 months after completion of treatment, which results in more than 6 years of median survival and a higher 5-year overall survival (OS). [ 3–5 ] For patients older than 65 years old and with non-transplantable initial treatment, bendamustine + rituximab (BR) or rituximab + bendamustine + Ara-C + cyclophosphamide, can be used for early induction therapy to improve patients' progression-free survival (PFS) and improve treatment efficiency. In addition, rituximab maintenance therapy has been shown to significantly prolong PFS in MCL. [ 6 ] Bruton's tyrosine kinase inhibitor (BTKi) is a novel small-molecule targeted drug that has been shown to have excellent efficacy as a single agent in relapsed MCL. The combination of BTKi with other drugs and its application in first-line MCL has also been reported. Ibrutinib treatment in combination with BR significantly prolonged PFS. The median PFS as assessed by the investigators was 80.6 months in the ibrutinib group, as compared with 52.9 months in the placebo group. [ 7 , 8 ] At present, there are few reports about the clinical application of BTKi combined with chemical immunotherapy in patients with initial MCL in China, especially about patients younger than 65 years old, who accepted rituximab combination with high-dose Ara-C. To meet the clinical needs of MCL patients, this study investigated the effect of advancing the use of BTKi in combination with chemotherapy.

Relapsed/Refractory Mantle Cell Lymphoma: Beyond BTK Inhibitors

Treatment of Relapsed/Refractory MCL

Treatment Landscape of Relapsed/Refractory Mantle Cell Lymphoma: An Updated Review

Advances in the treatment of mantle cell lymphoma with BTK inhibitors

Evaluating pirtobrutinib for the treatment of relapsed or refractory mantle cell lymphoma

Molecular Pathways Associated With Ibrutinib Resistance In Mantle Cell Lymphoma

Mantle Cell Lymphoma: Updates in the Management of Relapsed/Refractory Disease

Outcomes among Patients with Mantle Cell Lymphoma Post-Covalent BTK Inhibitor Therapy in the United States: A Real-World Electronic Medical Records Study

Novel treatment for mantle cell lymphoma – impact of BTK inhibitors and beyond

"The End of the Golden Weather": therapeutic strategies for mantle cell lymphoma relapsed or refractory to covalent BTK inhibitors

Real‐world experience among patients with relapsed/refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor failure in Europe: The SCHOLAR‐2 retrospective chart review study

BTKi combined with chemical immunotherapy in the initial treatment of aggressive mantle cell lymphoma: A retrospective study

Mantle cell lymphoma: 2019 update on the diagnosis, pathogenesis, prognostication, and management

Emerging therapies in mantle cell lymphoma

Chimeric Antigen Receptor T-cell Therapy: a Promising Treatment Modality for Relapsed/refractory Mantle Cell Lymphoma.

Mantle cell lymphoma management trends and novel agents: where are we going?

Ibrutinib Plus R-ICE Induces Remission in Blastoid Variant Mantle Cell Lymphoma with CNS Relapse

Immunotherapy in mantle cell lymphoma: anti-CD20-based therapy and beyond.

Mantle cell lymphoma: 2017 update on diagnosis, risk-stratification, and clinical management

Evaluating ibrutinib for the treatment of relapsed/refractory marginal zone lymphoma

Real-World Treatment Patterns, Survival, and Economic Burden Among Elderly MCL Patients Previously Treated With cBTKis